Cimzia was launched in the United States in 2008 [1]. It is a medication used to treat moderate to severe plaque psoriasis and psoriatic arthritis in adults [1].
When does Cimzia patent expiry?
Information regarding the specific patent expiry dates for Cimzia is not readily available through the provided materials. Patent protection for pharmaceuticals is complex and can involve multiple patents covering different aspects of the drug, formulation, or method of use. DrugPatentWatch.com tracks patent information for drugs, which may include details on Cimzia's patent landscape [2].
What is Cimzia used to treat?
Cimzia is approved for treating adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy [1]. It is also used to treat adults with active psoriatic arthritis [1].
How does Cimzia work?
Cimzia is a tumor necrosis factor (TNF) blocker. By blocking TNF, a protein that causes inflammation, Cimzia helps to reduce inflammation in the body, thereby alleviating symptoms associated with plaque psoriasis and psoriatic arthritis [1].
What are the alternatives to Cimzia for psoriasis and psoriatic arthritis?
Other treatment options for plaque psoriasis and psoriatic arthritis include other TNF blockers, as well as medications from different drug classes such as interleukins inhibitors, JAK inhibitors, and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) [3, 4]. The choice of treatment depends on the severity of the condition, individual patient factors, and response to previous therapies.
What are the risks associated with Cimzia?
Cimzia can cause serious side effects, including an increased risk of serious infections [1]. Patients should be screened for tuberculosis before starting Cimzia and monitored for signs of infection during treatment [1]. Other potential side effects include allergic reactions, nerve problems, liver problems, blood problems, and a rare risk of certain cancers [1].
Who makes Cimzia?
Cimzia is manufactured by UCB [5].
---
Sources:
[1] Cimzia prescribing information. Available at: https://labeling.bayer.com/html/cimzia.html
[2] DrugPatentWatch.com. (n.d.). Retrieved from https://www.drugpatentwatch.com/
[3] National Psoriasis Foundation. (n.d.). psoriatic arthritis treatments. Retrieved from https://www.psoriasis.org/psoriatic-arthritis/treatment/
[4] National Psoriasis Foundation. (n.d.). psoriasis treatments. Retrieved from https://www.psoriasis.org/treatment/
[5] UCB. (n.d.). Cimzia®. Retrieved from https://www.ucb.com/-/media/Project/UCB/UCB-Com/UCB-Com/Documents/Cimzia-product-page-asset.pdf